FDA approves Pfizer/Merck KGaA’s Bavencio in first line bladder cancerThe FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with Share XFDA approves Pfizer/Merck KGaA’s Bavencio in first line bladder cancerhttps://pharmaphorum.com/news/fda-approves-pfizer-merck-kgaas-bavencio-in-first-line-bladder-cancer/
NICE green lights Roche’s Rozlytrek for NTRK tumoursThe UK’s National Institute for Health and Care Excellence (NICE) has cleared Roche’s Rozlytrek for NTRK fusion-positive solid Share XNICE green lights Roche’s Rozlytrek for NTRK tumourshttps://pharmaphorum.com/news/nice-green-lights-roches-rozlytrek-for-ntrk-tumours/
After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
Mixed results for Roche drugs in prostate cancer and COVID-19Two eye-catching research projects involving drugs from Roche have produced disappointing trial results, after its prostate cancer drug Share XMixed results for Roche drugs in prostate cancer and COVID-19https://pharmaphorum.com/news/mixed-results-for-roche-drugs-in-prostate-cancer-and-covid-19/
Mereo raises $70m as TIGIT cancer drug progresses in clinicMereo BioPharma has raised $70m to develop its next-generation anti-TIGIT cancer checkpoint inhibitor drug. The finance round was led by OrbiMed and Share XMereo raises $70m as TIGIT cancer drug progresses in clinichttps://pharmaphorum.com/news/mereo-raises-70m-as-tigit-cancer-drug-progresses-in-clinic/
FDA clears emergency use of Roche test for COVID-19 ‘cytokine storm’Roche has been given a green light by the FDA to use one of its diagnostic tests to Share XFDA clears emergency use of Roche test for COVID-19 ‘cytokine storm’https://pharmaphorum.com/news/fda-clears-emergency-use-of-roche-test-for-covid-19-cytokine-storm/
FDA extends review of Novartis’ MS drug ofatumumabThe FDA has extended its review of Novartis’ potential multiple sclerosis drug ofatumumab, pushing back a decision on the repurposed Share XFDA extends review of Novartis’ MS drug ofatumumabhttps://pharmaphorum.com/news/fda-extends-review-of-novartis-ms-drug-ofatumumab/
Roche’s Tecentriq/Avastin combo gets liver cancer nodThe FDA has approved Roche’s combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular carcinoma (HCC) – Share XRoche’s Tecentriq/Avastin combo gets liver cancer nodhttps://pharmaphorum.com/news/roches-tecentriq-avastin-combo-gets-liver-cancer-nod/
Merck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancerMerck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, Share XMerck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancerhttps://pharmaphorum.com/news/merck-cos-keytruda-outperforms-chemo-in-msi-high-colorectal-cancer/
